{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:36:34Z","timestamp":1791218194670,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T00:00:00Z","timestamp":1506729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T00:00:00Z","timestamp":1506729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004417","name":"Global Fund to Fight AIDS, Tuberculosis and Malaria","doi-asserted-by":"publisher","award":["GF-OIG-13-012"],"award-info":[{"award-number":["GF-OIG-13-012"]}],"id":[{"id":"10.13039\/100004417","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s40261-017-0579-z","type":"journal-article","created":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T05:56:57Z","timestamp":1506751017000},"page":"9-17","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Comparison of Adverse Drug Reaction Profiles in Patients on Antiretroviral and Antitubercular Treatment in Zimbabwe"],"prefix":"10.1007","volume":"38","author":[{"given":"Josiah T.","family":"Masuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Precious","family":"Chipangura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla P.","family":"Nyambayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Stergachis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Star","family":"Khoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,30]]},"reference":[{"key":"579_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4081\/idr.2016.6570","volume":"8","author":"M Raviglione","year":"2016","unstructured":"Raviglione M, Sulis G. Tuberculosis 2015: burden, challenges and strategy for control and elimination. Infect Dis Rep. 2016;8:33\u20137.","journal-title":"Infect Dis Rep"},{"key":"579_CR2","unstructured":"WHO. WHO| TB\/HIV facts 2012\u20132013. WHO. World Health Organization; 2015. http:\/\/www.who.int\/hiv\/topics\/tb\/tbhiv_facts_2013\/en\/. Accessed 2 Oct 2016."},{"key":"579_CR3","unstructured":"USAID. HIV and AIDS| U.S. Agency for International Development. http:\/\/www.usaid.gov\/what-we-do\/global-health\/hiv-and-aids. Accessed 29 Sept 2016."},{"key":"579_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1513\/pats.201010-064WR","volume":"8","author":"NA Martinson","year":"2011","unstructured":"Martinson NA, Hoffmann CJ, Chaisson RE. Epidemiology of tuberculosis and HIV: recent advances in understanding and responses. Proc Am Thorac Soc. 2011;8:288\u201393.","journal-title":"Proc Am Thorac Soc"},{"issue":"Suppl 3","key":"579_CR5","doi-asserted-by":"publisher","first-page":"S201","DOI":"10.1086\/651492","volume":"50","author":"H Getahun","year":"2010","unstructured":"Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis. 2010;50(Suppl 3):S201\u20137.","journal-title":"Clin Infect Dis"},{"key":"579_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1128\/CMR.00042-10","volume":"24","author":"C Kwan","year":"2011","unstructured":"Kwan C, Ernst JD. HIV and tuberculosis: A deadly human syndemic. Clin Microbiol Rev. 2011;24:351\u201376.","journal-title":"Clin Microbiol Rev"},{"key":"579_CR7","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1097\/00002030-200009080-00015","volume":"14","author":"E Girardi","year":"2000","unstructured":"Girardi E, Antonucci G, Vanacore P, Libanore M, Errante I, Matteelli A, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS. 2000;14:1985\u201391.","journal-title":"AIDS"},{"key":"579_CR8","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(02)08904-3","volume":"359","author":"M Badri","year":"2002","unstructured":"Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. The Lancet. 2002;359:2059\u201364.","journal-title":"The Lancet"},{"key":"579_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/01.qai.0000230521.86964.86","volume":"43","author":"W Manosuthi","year":"2006","unstructured":"Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV\/tuberculosis-coinfected patients with and without antiretroviral therapy. JAIDS J Acquir Immune Defic Syndr. 2006;43:42\u20136.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"579_CR10","doi-asserted-by":"crossref","unstructured":"McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis [Internet]. 2007;196:S63\u201375.","DOI":"10.1086\/518655"},{"key":"579_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1258\/ijsa.2008.008361","volume":"20","author":"DJB Marks","year":"2009","unstructured":"Marks DJB, Dheda K, Dawson R, Ainslie G, Miller RF. Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS. 2009;20:339\u201345.","journal-title":"Int J STD AIDS"},{"key":"579_CR12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1086\/521150","volume":"45","author":"R Subbaraman","year":"2007","unstructured":"Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis. 2007;45:1093\u2013101.","journal-title":"Clin Infect Dis"},{"key":"579_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12981-016-0106-y","volume":"13","author":"W Manosuthi","year":"2016","unstructured":"Manosuthi W, Wiboonchutikul S, Sungkanuparph S. Integrated therapy for HIV and tuberculosis. AIDS Res Ther. 2016;13:22.","journal-title":"AIDS Res Ther"},{"key":"579_CR14","doi-asserted-by":"publisher","first-page":"e904957","DOI":"10.1155\/2014\/904957","volume":"2014","author":"JN Kadima","year":"2014","unstructured":"Kadima JN, Mukanyangezi MF, Uwizeye CB. Effectiveness and safety of concurrent use of first-line antiretroviral and antituberculous drugs in Rwanda. J Trop Med. 2014;2014:e904957.","journal-title":"J Trop Med"},{"key":"579_CR15","unstructured":"World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. World Health. 2011;1:142. http:\/\/whqlibdoc.who.int\/publications\/2011\/9789241500708_eng.pdf. Accessed 1 Oct 2016."},{"key":"579_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/DHPS.S68837","volume":"6","author":"JT Denholm","year":"2014","unstructured":"Denholm JT, McBryde ES, Eisen DP, Penington JS, Chen C, Street AC. Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study. Drug Healthc Patient Saf. 2014;6:145\u20139.","journal-title":"Drug Healthc Patient Saf"},{"key":"579_CR17","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1164\/rccm.200911-1783OC","volume":"182","author":"Z Tedla","year":"2010","unstructured":"Tedla Z, Nyirenda S, Peeler C, Agizew T, Sibanda T, Motsamai O, et al. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in HIV-infected adults in Botswana. Am J Respir Crit Care Med. 2010;182:278\u201385.","journal-title":"Am J Respir Crit Care Med"},{"key":"579_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.5588\/ijtld.12.0427","volume":"17","author":"EH Decloedt","year":"2013","unstructured":"Decloedt EH, Mwansa-Kambafwile J, Van Der Walt JS, McIlleron H, Denti P, Smith P, et al. The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals. Int J Tuberc Lung Dis. 2013;17:333\u20135.","journal-title":"Int J Tuberc Lung Dis"},{"key":"579_CR19","first-page":"FC01","volume":"9","author":"S Sadiq","year":"2015","unstructured":"Sadiq S, Khajuria V, Tandon VR, Mahajan A, Singh JB. Adverse drug reaction profile in patients on anti-tubercular treatment alone and in combination with highly active antiretroviral therapy. J Clin Diagnostic Res. 2015;9:FC01\u20134.","journal-title":"J Clin Diagnostic Res"},{"key":"579_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40264-015-0387-4","volume":"39","author":"HH Ampadu","year":"2016","unstructured":"Ampadu HH, Hoekman J, de Bruin ML, Pal SN, Olsson S, Sartori D, et al. Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase\u00ae. Drug Saf. 2016;39:335\u201345.","journal-title":"Drug Saf"},{"key":"579_CR21","doi-asserted-by":"crossref","unstructured":"Muula AS, Ngulube TJ, Siziya S, Makupe CM, Umar E, Prozesky HW et al. Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. BMC Public Health. 2007;7:63. http:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/1471-2458-7-63. Accessed 6 June 2017.","DOI":"10.1186\/1471-2458-7-63"},{"key":"579_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/ijpp.12078","volume":"22","author":"J Marques","year":"2014","unstructured":"Marques J, Ribeiro-Vaz I, Pereira AC, Pol\u00f5nia J. A survey of spontaneous reporting of adverse drug reactions in 10\u00a0years of activity in a pharmacovigilance centre in Portugal. Int J Pharm Pract. 2014;22:275\u201382.","journal-title":"Int J Pharm Pract"},{"key":"579_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40801-015-0054-1","volume":"3","author":"G Ozcan","year":"2016","unstructured":"Ozcan G, Aykac E, Kasap Y, Nemutlu NT, Sen E, Aydinkarahaliloglu ND. Adverse drug reaction reporting pattern in Turkey: analysis of the national database in the context of the first pharmacovigilance legislation. Drug Real World Outcome. 2016;3:33\u201343.","journal-title":"Drug Real World Outcome"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-017-0579-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0579-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0579-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:17:19Z","timestamp":1659089839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-017-0579-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,30]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["579"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0579-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,30]]},"assertion":[{"value":"30 September 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All the authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The targeted spontaneous reporting programme was funded through the Global Fund, Grant GF-OIG-13-012. Funding was also provided by WHO, UNICEF and MCAZ. The ADR reports used in this study were submitted during the targeted spontaneous reporting programme. However, no direct funding from the Global Fund grant and other donor partners was received in the conduct of this study and during preparation of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}